Evidence map›Paper›PMID 25510159›Full record

ArticleAging cell2015

Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes.

Srinivas Ayyadevara, Meenakshisundaram Balasubramaniam, Yuan Gao, Li-Rong Yu, Ramani Alla, Robert Shmookler Reis

Open access · goldAbstract read
In one paragraph

Article in Aging cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 57 citations in OpenAlex.

  1. The aggregate proteome ofFrontiers in aging neuroscience · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. A novel knockout mouse for the small EDRK-rich factor 2 (Serf2) showing developmental and other deficits.Mammalian genome : official journal of the International Mammalian Genome Society · 2021
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Srinivas AyyadevaraMcClellan Veterans Medical Center, Central Arkansas Veterans Healthcare Service, Little Rock, AR, 72205, USA; Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Meenakshisundaram Balasubramaniam
Yuan Gao
Li-Rong Yu
Ramani Alla
Robert Shmookler Reis
National Center for Toxicological Research · USUniversity of Arkansas for Medical Sciences · USCentral Arkansas Veterans Healthcare System · USUniversity of Arkansas at Little Rock · US

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
VIRULENCE MECHANISMS IN ESCHERICHIA COLIP20RR016460 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI HENSLEY, LORI · 2001 to 2011
$33.1M
RESOURCE CORE 3: ANALYTICAL COREP30AG028718 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI WEI, JEANNE Y · 2011 to 2015
$5.1M
NCRR NIH HHS P20 RR016460NIA NIH HHS P30 AG028718NIA NIH HHS P30-AG028718NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

Age-dependent neurodegenerative diseases progressively form aggregates containing both shared components (e.g., TDP-43, phosphorylated tau) and proteins specific to each disease. We investigated whether diverse neuropathies might have additional aggregation-prone proteins in common, discoverable by proteomics. Caenorhabditis elegans expressing unc-54p/Q40::YFP, a model of polyglutamine array diseases such as Huntington's, accrues aggregates in muscle 2-6 days posthatch. These foci, isolated on antibody-coupled magnetic beads, were characterized by high-resolution mass spectrometry. Three Q40::YFP-associated proteins were inferred to promote aggregation and cytotoxicity, traits reduced or delayed by their RNA interference knockdown. These RNAi treatments also retarded aggregation/cytotoxicity in Alzheimer's disease models, nematodes with muscle or pan-neuronal Aβ₁₋₄₂ expression and behavioral phenotypes. The most abundant aggregated proteins are glutamine/asparagine-rich, favoring hydrophobic interactions with other random-coil domains. A particularly potent modulator of aggregation, CRAM-1/HYPK, contributed < 1% of protein aggregate peptides, yet its knockdown reduced Q40::YFP aggregates 72-86% (P < 10(-6) ). In worms expressing Aβ₁₋₄₂, knockdown of cram-1 reduced β-amyloid 60% (P < 0.002) and slowed age-dependent paralysis > 30% (P < 10(-6)). In wild-type worms, cram-1 knockdown reduced aggregation and extended lifespan, but impaired early reproduction. Protection against seeded aggregates requires proteasome function, implying that normal CRAM-1 levels promote aggregation by interfering with proteasomal degradation of misfolded proteins. Molecular dynamic modeling predicts spontaneous and stable interactions of CRAM-1 (or human orthologs) with ubiquitin, and we verified that CRAM-1 reduces degradation of a tagged-ubiquitin reporter. We propose that CRAM-1 exemplifies a class of primitive chaperones that are initially protective and highly beneficial for early reproduction, but ultimately impair aggregate clearance and limit longevity.

Indexed as

Protein AggregatesAmyloid beta-PeptidesAnimalsBlotting, WesternCaenorhabditis elegansCaenorhabditis elegans ProteinsCell DeathDisease Models, AnimalFertilityFluorescent Antibody TechniqueGene Knockdown TechniquesMolecular Dynamics SimulationNeurodegenerative DiseasesProteasome Endopeptidase ComplexProteasome InhibitorsProtein MultimerizationAmyloid beta-PeptidesCaenorhabditis elegans ProteinsProteasome Endopeptidase ComplexProteasome InhibitorsProtein AggregatesUbiquitinAlzheimer (disease)C. elegansHuntington (disease)neurodegenerationproteasome(protein) aggregation

Identifiers

PMID25510159
PMCPMC4326912
OpenAlexW2014536738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.